Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU)
Latest Information Update: 02 Jun 2023
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms LURBICLIN
Most Recent Events
- 26 May 2023 According to PharmaMar media release, data from this study will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
- 05 Jan 2023 Status changed from active, no longer recruiting to completed.
- 28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Jan 2023.